Challenging Pharma Patents
Guan discusses the controversial strategy of shorting drug companies by challenging their patents, highlighting the mixed reactions from the pharma industry and patent lawyers. While some view the profit motive as a valid reason to contest weak patents, companies like Celgene argue that hedge fund managers lack a genuine economic interest. Despite facing criticism, recent decisions have favored the challengers, validating their approach and raising questions about the future of patent enforcement in the pharmaceutical sector.In this clip
From this podcast
Odd Lots
Episode 4: Can a Hedge Funder Cut Prescription Drug Costs?
Related Questions